Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicohort study of GB268 alone or in combination for advanced or metastatic breast cancer
CTR20262740Phase 2Active
- Sponsor
- Eddingpharm
- Start
- Aug 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GB268 in breast cancer, sponsored by Eddingpharm. Started Aug 2026; status: active.
02
Drugs
GB268
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20262740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262740.